Literature DB >> 29555202

Association of vitamin D receptor gene polymorphisms with serum 25(OH)D levels and metabolic syndrome in Thai population.

Boonnisa Sangkaew1, Manit Nuinoon2, Nutjaree Jeenduang3.   

Abstract

Metabolic syndrome (MetS) increases the risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). The vitamin D receptor gene (VDR) polymorphisms have been found associated with MetS and serum 25(OH)D levels but these associations remain controversial. The aim of this study was to investigate the relationship between the VDR polymorphisms and MetS, metabolic components, and serum 25(OH)D levels within the Thai population. A case-control study included 237 participants with MetS according to the MetS diagnostic criteria of NCEP ATPIII and 376 controls. Anthropometric data, blood pressure, lipid profiles, serum 25 (OH)D, and fasting blood glucose were measured. VDR FokI, BsmI, TaqI, and Cdx2 polymorphisms were genotyped by using PCR-HRM. There were no significant differences in the frequencies of VDR genotypes and alleles between MetS and the control groups. VDR TaqI TT, and BsmI BB + Bb genotypes were associated with lower 25(OH)D levels (p < 0.05) in comparison to TaqI Tt, and BsmI bb genotypes in the MetS group, respectively. In addition, the VDR Cdx2 GG genotype was associated with higher WC compared with the AG genotype in all subjects (p < 0.05). Logistic regression analysis revealed that BB + Bb genotypes of the VDR BsmI had significantly increased the odds ratio (OR) of hypertriglyceridemia when compared with the bb genotype (OR 1.87; 95% CI 1.10-3.19, p = 0.022). In conclusion, VDR BsmI variant was associated with hypertriglyceridemia and may be predisposed to developing MetS. VDR TaqI and BsmI polymorphisms seems to influence serum 25(OH)D levels in MetS subjects, while Cdx2 polymorphism may influence WC in all subjects.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Metabolic syndrome; Polymorphism; Serum 25(OH)D; VDR

Mesh:

Substances:

Year:  2018        PMID: 29555202     DOI: 10.1016/j.gene.2018.03.047

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  The Associations Between Vitamin D Receptor BsmI and ApaI Polymorphisms and Obesity in Korean Patients with Type 2 Diabetes Mellitus.

Authors:  Sang Won Nam; Jinwoo Choi; Hyun Jeong Jeon; Tae Keun Oh; Dong-Hwa Lee
Journal:  Diabetes Metab Syndr Obes       Date:  2021-02-10       Impact factor: 3.168

2.  The association between serum 25-hydroxyvitamin D concentrations and serum lipids in the Southern Thai population.

Authors:  Nutjaree Jeenduang; Boonnisa Sangkaew
Journal:  Arch Med Sci       Date:  2020-11-20       Impact factor: 3.318

3.  Vitamin D-Related Single Nucleotide Polymorphisms as Risk Biomarker of Cardiovascular Disease.

Authors:  Paula González Rojo; Cristina Pérez Ramírez; José María Gálvez Navas; Laura Elena Pineda Lancheros; Susana Rojo Tolosa; María Del Carmen Ramírez Tortosa; Alberto Jiménez Morales
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

4.  Association of vitamin D receptor polymorphisms with metabolic syndrome-related components: A cross-sectional study.

Authors:  Ting Jin; Weina Lu; Xiaoqin Gong; Jiaqiang Zhou; Fang Wu
Journal:  J Clin Lab Anal       Date:  2021-05-19       Impact factor: 2.352

5.  Genetic associations of vitamin D receptor polymorphisms with advanced liver fibrosis and response to pegylated interferon-based therapy in chronic hepatitis C.

Authors:  Kessarin Thanapirom; Sirinporn Suksawatamnuay; Wattana Sukeepaisarnjaroen; Pisit Tangkijvanich; Panarat Thaimai; Rujipat Wasitthankasem; Yong Poovorawan; Piyawat Komolmit
Journal:  PeerJ       Date:  2019-09-11       Impact factor: 2.984

Review 6.  Clinical Significance of Analysis of Vitamin D Status in Various Diseases.

Authors:  Magdalena Kowalówka; Anna K Główka; Marta Karaźniewicz-Łada; Grzegorz Kosewski
Journal:  Nutrients       Date:  2020-09-11       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.